https://clinical-hematology.org/prof-mohamad-mohty/2021-06-15T21:23:13+00:00https://clinical-hematology.org/dr-jim-omel/2021-06-15T21:27:35+00:00https://clinical-hematology.org/dr-jordan-gauthier/2021-06-15T21:28:36+00:00https://clinical-hematology.org/ruben-messa/2021-06-25T06:41:37+00:00https://clinical-hematology.org/mohamad-mohty-eah-2021/2021-06-25T06:39:45+00:00https://clinical-hematology.org/arnon-nagler/2021-06-22T13:48:20+00:00https://clinical-hematology.org/jesus-g-berdeja-results-of-the-cartitude-1-study/2021-06-27T09:38:23+00:00https://clinical-hematology.org/luciano-j-costa-the-role-of-auto-in-myeloma-based-on-the-asco-21-data/2021-07-01T11:46:31+00:00https://clinical-hematology.org/saad-usmani-take-home-messages-from-asco-and-eha-2021/2021-07-01T11:56:33+00:00https://clinical-hematology.org/mehdi-hamadani-recently-released-zuma-7-trial-results/2021-07-01T12:02:57+00:00https://clinical-hematology.org/gram-jackson-recently-released-paper-on-improving-prognostic-assignment-in-older-adults-with-mm/2021-07-10T07:11:50+00:00https://clinical-hematology.org/nitin-jain-therapy-of-cll-whats-new-at-eha-2021/2021-07-10T07:20:04+00:00https://clinical-hematology.org/anna-sureda-therapy-of-lymphomas-whats-new-at-eha-2021/2021-07-10T07:23:40+00:00https://clinical-hematology.org/jurgen-kuball-gammadelta-t-cells/2021-07-16T19:05:41+00:00https://clinical-hematology.org/naveen-pemmaraju-novel-therapeutic-approaches-in-bpdcn/2021-07-16T19:06:20+00:00https://clinical-hematology.org/monzr-al-malki-the-role-of-post-cyclophosphamide-for-gvhd-prophylaxis-in-the-mismatched-unrelated-setting/2021-07-16T19:20:11+00:00https://clinical-hematology.org/alex-lazaryan-belumosudils-fda-approval-for-cgvhd/2021-07-19T11:36:45+00:00https://clinical-hematology.org/robert-zeiser-reach3-trial-results/2021-07-19T11:38:59+00:00https://clinical-hematology.org/christopher-hourigan-how-to-distinguish-to-acute-myeloid-leukemia-from-non-malignant-clonal-hematopoiesis/2021-09-09T14:49:42+00:00https://clinical-hematology.org/annalisa-ruggreri-haplo-versus-matched-unrelated-transplant-at-the-era-of-post-cyclophosphamide/2021-09-09T15:44:58+00:00https://clinical-hematology.org/prof-arnon-kater-state-of-the-art-therapy-in-cll/2021-11-21T16:16:16+00:00https://clinical-hematology.org/prof-iskra-pusic-recent-updated-in-acute-gvhd/2021-11-21T16:18:34+00:00https://clinical-hematology.org/prof-farhad-ravandi-mrd-in-aml/2021-11-21T16:21:00+00:00https://clinical-hematology.org/prof-sebastian-giebel-car-t-cells-for-adult-all/2022-03-27T20:49:58+00:00https://clinical-hematology.org/dr-eolia-brissot-approval-of-maribvir-for-post-transplant-cytomegalovirus-infection/2022-03-27T20:51:22+00:00https://clinical-hematology.org/prof-mohamad-mohty-new-treatments-for-refractrory-acute-gvhd/2022-03-29T14:02:12+00:00https://clinical-hematology.org/prof-paul-richardson-melflufen-for-the-treatement-of-relapsed-refractory-myeloma/2022-07-08T10:52:25+00:00https://clinical-hematology.org/prof-selim-corbacioglu-the-importance-of-veno-occlusive-disease-prophylaxis/2022-07-26T20:47:32+00:00https://clinical-hematology.org/prof-meral-beksac-the-recent-developments-in-the-field-of-bispecific-t-cell-engagers/2022-07-28T08:49:55+00:00https://clinical-hematology.org/dr-adi-nagler-single-cell-sequencing-to-chronic-lymphocytic-leukemia/2022-09-20T07:34:21+00:00https://clinical-hematology.org/prof-mikkael-sekeres-azacitidine-plus-venetoclax-for-myelodysplastic-syndromes/2022-09-20T13:10:34+00:00https://clinical-hematology.org/prof-he-huang-non-viral-specifically-targeted-car-t-cells-achieve-high-safety-and-efficacy-in-b-nhl/2022-09-21T08:19:47+00:00https://clinical-hematology.org/dr-areej-el-jawahri-quality-of-life-psychological-distress-and-prognostic-perceptions-in-caregivers-of-patients-with-multiple-myeloma/2022-10-06T14:41:38+00:00https://clinical-hematology.org/prof-mohamed-kharfan-dabaja-positive-topline-results-from-final-progression-free-survival-analysis-of-zanubrutinib-compared-to-ibrutinib-in-cll/2022-10-17T08:48:06+00:00https://clinical-hematology.org/dr-eolia-brissot-positive-opinion-of-the-chmp-on-tabelecleucel-for-the-treatment-of-epstein-barr-virus-positive-post-transplant-lymphoproliferative-disease/2022-10-24T08:28:01+00:00https://clinical-hematology.org/prof-mohamad-mohty-fda-breakthrough-therapy-designation-for-elranatamab-in-relapsed-or-refractory-multiple-myeloma/2022-11-07T09:58:15+00:00https://clinical-hematology.org/prof-marion-subklewe-t-cell-exhaustion-induced-by-continuous-bispecific-molecule-exposure/2022-11-11T07:58:01+00:00https://clinical-hematology.org/prof-florent-malard-the-first-microbiota-therapy-approved-by-the-us-fda/2022-12-06T11:42:16+00:00https://clinical-hematology.org/dr-doris-hansen-idecabtagene-vicleucel-for-relapsed-refractory-multiple-myeloma-real-world-experience-from-the-myeloma-car-t-consortium/2023-01-22T07:12:06+00:00https://clinical-hematology.org/prof-christoph-stein-thoeringer-role-of-the-gut-microbiome-in-car-t-cell-therapy/2023-04-03T16:12:03+00:00https://clinical-hematology.org/dr-paula-rodriguez-otero-ide-cel-or-standard-regimens-in-relapsed-and-refractory-multiple-myeloma/2023-04-23T12:10:58+00:00https://clinical-hematology.org/dr-bhagirathbhai-dholaria-omisirge-allogeneic-cord-blood-based-cell-therapy-approved-to-reduce-risk-of-infection-following-stem-cell-transplantation/2023-08-20T08:53:28+00:00https://clinical-hematology.org/dr-oluwole-olalekan-approval-of-polatuzumab-vedotin-plus-r-chp-for-previously-untreated-dlbcl/2023-08-20T08:52:36+00:00https://clinical-hematology.org/https-soundcloud-com-cme-congresses-bu-flu-versus-bu-cy-for-aml-patients-undergoing-haplo-a-multi-center-randomized-phase-iii-trialsi7f6afc60a6c14cc6b1f05f59413d118futm_sourceclipboardutm_mediu/2023-08-20T08:17:37+00:00https://clinical-hematology.org/dr-jordan-gauthier-cd19-car-t-cell-therapy-prophylactic-anakinra-in-relapsed-or-refractory-lymphoma-phase-2-trial-interim-results/2023-08-20T08:16:13+00:00https://clinical-hematology.org/dr-olalekan-oluwole-his-take-on-the-overall-survival-update-from-the-randomized-zuma-7-trial/2023-08-20T08:15:00+00:00https://clinical-hematology.org/dr-samer-al-hadidi-risk-of-infections-associated-with-the-use-of-bispecific-antibodies-in-multiple-myeloma/2023-08-20T08:13:42+00:00https://clinical-hematology.org/dr-tania-jain-haploidentical-donor-hematopoietic-cell-transplantation-for-mds-mpn-overlap-neoplasms-results-from-a-north-american-collaboration/2023-08-20T08:13:11+00:00https://clinical-hematology.org/dr-jayastu-senapati-prognostic-impact-of-splicing-factor-mutations-in-patients-with-newly-diagnosed-aml/2023-08-20T08:12:17+00:00https://clinical-hematology.org/dr-ashwin-kishtagari-his-take-on-the-recent-approval-of-quizartinib-by-fda-in-aml/2023-08-20T08:11:42+00:00https://clinical-hematology.org/prof-michael-jordan-hlh-like-toxicities-predict-poor-survival-after-the-use-of-tisagenlecleucel-in-children-and-young-adults-with-b-all/2023-08-20T08:11:01+00:00https://clinical-hematology.org/sept-5th-2023-prof-uwe-platzbecker-recent-approval-of-luspatercept-as-first-line-treatment-of-anemia-in-adults-with-lower-risk-mds-who-may-require-transfusions/2023-09-04T09:13:58+00:00https://clinical-hematology.org/sept-7th-2023-prof-alvaro-urbano-fractionated-initial-infusion-and-booster-dose-of-ari0002h-a-humanised-bcma-directed-car-t-cell-therapy-for-patients-with-relapsed-or-refractory-multiple-myeloma/2023-09-06T07:40:11+00:00https://clinical-hematology.org/sept-12th-2023-prof-christina-peters-poverty-and-relapse-risk-in-children-with-all-a-childrens-oncology-group-study-aall03n1-report/2023-09-10T05:56:01+00:00https://clinical-hematology.org/sept-18th-2023-prof-ephraim-fuchs-cytokine-release-syndrome-in-haploidentical-stem-cell-transplant-may-impact-t-cell-recovery-and-relapse/2023-09-18T07:55:03+00:00https://clinical-hematology.org/sept-25th-2023-dr-akshay-sharma-crispr-cas9-editing-of-the-hbg1-and-hbg2-promoters-to-treat-sickle-cell-disease/2023-09-20T11:10:36+00:00https://clinical-hematology.org/oct-2nd-2023-dr-paul-richardson-mezigdomide-plus-dexamethasone-in-relapsed-and-refractory-myeloma/2023-09-21T07:15:03+00:00https://clinical-hematology.org/oct-9th-2023-dr-philippe-armand-five-year-follow-up-of-keynote-087/2023-09-27T07:33:50+00:00https://clinical-hematology.org/oct-16th-2023-dr-enrique-ocio-delflufen-plus-dexamethasone-and-daratumumab-or-bortezomib-in-relapsed-refractory-mm/2023-10-12T06:33:16+00:00https://clinical-hematology.org/oct-23rd-2023-prof-didier-blaise-real-world-experience-of-car-t-cell-therapy-in-older-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2023-10-22T07:35:02+00:00https://clinical-hematology.org/oct-30th-2023-prof-robert-zeiser-phase-2-study-of-natalizumab-plus-standard-corticosteroid-treatment-for-high-risk-acute-gvhd/2023-10-29T10:30:21+00:00https://clinical-hematology.org/nov-6th-2023-prof-attilio-olivieri-incidence-clinical-presentation-risk-factors-outcomes-and-biomarkers-in-de-novo-late-acute-gvhd/2023-11-05T06:48:14+00:00https://clinical-hematology.org/nov-14th-2023-dr-bipin-savani-vitamin-c-and-d-supplementation-in-acute-myeloid-leukemia/2023-11-08T06:35:37+00:00https://clinical-hematology.org/nov-21st-2023-prof-moshe-mittelman-a-randomized-comparison-of-cpx-351-and-flag-ida-in-adverse-karyotype-aml-and-high-risk-mds-the-uk-ncri-aml19-trial/2023-11-19T06:54:42+00:00https://clinical-hematology.org/nov-28th-2023-prof-ibrahim-yakoub-agha-nonrelapse-mortality-after-car-t-cell-therapy-for-large-b-cell-lymphoma-a-lysa-study-from-the-descar-t-registry/2023-11-21T11:16:59+00:00https://clinical-hematology.org/dec-6th-2023-prof-wolfgang-bethge-outcomes-of-axicabtagene-ciloleucel-in-pmbcl-compare-favorably-with-those-in-dlbcl-a-gla-drst-registry-study/2023-12-03T08:05:44+00:00https://clinical-hematology.org/dec-12th-2023-prof-arnold-ganser-how-i-treat-refractory-and-relapsed-acute-myeloid-leukemia/2023-12-06T07:49:31+00:00https://clinical-hematology.org/dec-19th-2023-prof-florent-malard-gut-microbiota-diversity-before-allogeneic-hematopoietic-stem-cell-transplantation-as-a-predictor-of-mortality-in-children/2023-12-13T10:37:16+00:00https://clinical-hematology.org/jan-8th-2024-david-valcarcel-adrian-mosquera-machine-learning-improves-risk-stratification-in-myelodysplastic-neoplasms-an-analysis-of-the-spanish-group-of-myelodysplastic-syndromes/2024-01-07T07:28:24+00:00https://clinical-hematology.org/jan-23rd-2024-prof-daniel-wolff-safety-and-efficacy-of-axatilimab-at-3-different-doses-in-patients-with-cgvhd-disease-agave-201/2024-01-21T08:20:40+00:00https://clinical-hematology.org/feb-2nd-2024-dr-paula-rodriguez-otero-the-european-medicines-agencys-committee-for-medicinal-products-for-human-use-chmp-has-recommended-marketing-authorization-approval-for-idecabtagene/2024-02-02T07:23:05+00:00https://clinical-hematology.org/feb-5th-2024-prof-ali-bazarbachi-sorafenib-plus-intensive-chemotherapy-in-newly-diagnosed-flt3-itd-aml-a-randomized-placebo-controlled-study-by-the-allg/2024-02-04T08:04:14+00:00https://clinical-hematology.org/feb-14th-2024-dr-joshua-fein-simple-score-of-albumin-and-crp-predicts-high-grade-toxicity-in-patients-with-multiple-myeloma-receiving-car-t-therapy/2024-02-11T09:53:40+00:00https://clinical-hematology.org/feb-21st-2024-guido-ghilardi-marco-ruella-t-cell-lymphoma-and-secondary-primary-malignancy-risk-after-commercial-car-t-cell-therapy/2024-02-22T09:21:29+00:00https://clinical-hematology.org/feb-26th-2024-prof-marion-subklewe-recent-bendamustine-treatment-before-apheresis-has-a-negative-impact-on-outcomes-in-patients-with-large-b-cell-lymphoma-receiving-chimeric-antigen-receptor-t-cell/2024-02-25T08:13:18+00:00https://clinical-hematology.org/march-6th-2024-prof-katy-rezvani-safety-efficacy-and-determinants-of-response-of-allogeneic-cd19-specific-car-nk-cells-in-cd19-b-cell-tumors-a-phase-1-2-trial/2024-03-04T08:22:05+00:00https://clinical-hematology.org/march-11th-2024-dr-adi-zoref-lorenz-malignancy-associated-hemophagocytic-lymphohistiocytosis-in-sweden-incidence-clinical-characteristics-and-survival-2/2024-03-10T07:00:13+00:00https://clinical-hematology.org/march-20th-2024-prof-michael-schmitt-efficacy-and-safety-of-extended-duration-letermovir-prophylaxis-in-recipients-of-hematopoietic-stem-cell-transplantation-at-risk-of-cytomegalovirus-infection/2024-03-12T14:17:08+00:00https://clinical-hematology.org/march-25th-2024-prof-olaf-penack-prophylaxis-and-management-of-graft-versus-host-disease-after-stem-cell-transplantation-for-haematological-malignancies-updated-consensus-recommendations-of-the-eu/2024-03-20T09:54:58+00:00https://clinical-hematology.org/april-10th-2024-dr-ofir-wolach-molecular-mrd-is-strongly-prognostic-in-patients-with-npm1-mutated-aml-receiving-venetoclax-based-nonintensive-therapy/2024-04-08T07:25:13+00:00https://clinical-hematology.org/april-17th-2024-prof-nigel-russell-fludarabine-cytarabine-granulocyte-colony-stimulating-factor-and-idarubicin-with-gemtuzumab-ozogamicin-improves-event-free-survival-in-younger-patients-with-ne/2024-04-14T09:41:37+00:00https://clinical-hematology.org/april-30th-2024-dr-fadi-haddad-prof-elias-jabbour-phase-2-study-of-inotuzumab-ozogamicin-for-measurable-residual-disease-in-acute-lymphoblastic-leukemia-in-remission/2024-04-30T07:00:18+00:00https://clinical-hematology.org/may-7th-2024-prof-ibrahim-yakoub-agha-three-year-follow-up-analysis-of-axicabtagene-ciloleucel-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-zuma-5/2024-05-02T09:07:03+00:00https://clinical-hematology.org/may-14th-2024-prof-didier-blaise-sequential-cd7-car-t-cell-therapy-and-allogeneic-hsct-without-gvhd-prophylaxis/2024-05-09T09:19:49+00:00https://clinical-hematology.org/may-20th-2024-dr-lorenz-bastian-developmental-trajectories-and-cooperating-genomic-events-define-molecular-subtypes-of-bcrabl1-positive-all/2024-05-15T11:09:33+00:00https://clinical-hematology.org/may-24th-2024-dr-ruth-namazzi-hydroxyurea-reduces-infections-in-children-with-sickle-cell-anemia-in-uganda/2024-05-21T07:05:01+00:00https://clinical-hematology.org/june-3rd-2024-prof-saad-usmani-cd8-effector-t-cells-enhance-teclistamab-response-in-bcma-exposed-and-naive-multiple-myeloma/2024-05-29T06:46:47+00:00https://clinical-hematology.org/june-11th-2024-dr-zachariah-defilipp-flares-of-acute-graft-versus-host-disease-a-mount-sinai-acute-gvhd-international-consortium-analysis/2024-06-06T10:12:14+00:00https://clinical-hematology.org/june-17th-2024-prof-saad-usmani-antigen-escape-as-a-shared-mechanism-of-resistance-to-bcma-directed-therapies-in-multiple-myeloma-2/2024-06-16T07:54:57+00:00https://clinical-hematology.org/june-24th-2024-dr-tamar-tadmor-supplement-of-vitamin-d-for-early-stage-chronic-lymphocytic-leukemia-patients-is-associated-with-a-longer-time-to-first-treatment/2024-06-16T07:59:45+00:00https://clinical-hematology.org/july-7th-2024-dr-anand-patel-treatment-approach-and-outcomes-of-patients-with-accelerated-blast-phase-myeloproliferative-neoplasms-in-the-current-era/2024-07-04T15:03:17+00:00https://clinical-hematology.org/july-16th-2024-prof-madhav-dhodapkar-linvoseltamab-for-treatment-of-relapsed-refractory-multiple-myeloma/2024-07-16T06:49:04+00:00https://clinical-hematology.org/july-22nd-2024-dr-kai-rejeski-a-systematic-review-and-meta-analysis-of-nonrelapse-mortality-after-car-t-cell-therapy/2024-07-16T12:38:00+00:00https://clinical-hematology.org/august-26th-2024-prof-olaf-penack-how-risky-is-a-second-allogeneic-stem-cell-transplantation/2024-08-06T08:16:01+00:00https://clinical-hematology.org/september-2nd-2024-prof-mark-litzow-blinatumomab-for-mrd-negative-acute-lymphoblastic-leukemia-in-adults/2024-08-28T12:19:56+00:00https://clinical-hematology.org/september-13th-2024-prof-ellis-martin-differential-effects-of-itacitinib-fedratinib-and-ruxolitinib-in-mouse-models-of-hemophagocytic-lymphohistiocytosis/2024-09-12T08:55:26+00:00https://clinical-hematology.org/september-20th-2024-prof-qian-jiang-a-predictive-model-for-therapy-failure-in-cml-patients-receiving-tyrosine-kinase-inhibitor-therapy/2024-09-16T08:56:30+00:00